An Emerging Phenomenon: Weight Gain After Initiation of Antiretroviral Therapy in Patients With HIV Medscape InDiscussion: HIV

Drs Michael S. Saag and Roger Bedimo discuss weight gain after starting antiretroviral therapy, including risk factors, long-term outcomes, and patients' well-being.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/986507). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Weight Gain on INSTI-Based HIV Antiretrovirals https://www.medscape.com/viewarticle/916095#vp_2
Lipodystrophy in HIV Clinical Presentation https://emedicine.medscape.com/article/1082199-clinical
Protease Inhibitors' Metabolic Side Effects: Cholesterol, Triglycerides, Blood Sugar, and 'Crix Belly.' Interview With Lisa Capaldini, MD. Interview by John S. James https://pubmed.ncbi.nlm.nih.gov/11364559/
Reduced Survival After Serious Non-AIDS Complications https://www.medscape.com/viewarticle/721773
HIV Protease Inhibitor-Related Lipodystrophy Syndrome https://pubmed.ncbi.nlm.nih.gov/10860898/
Antiretroviral Therapy for HIV Infection https://emedicine.medscape.com/article/1533218-overview
Integrase Strand Transfer Inhibitor (INSTI) https://clinicalinfo.hiv.gov/en/glossary/integrase-strand-transfer-inhibitor-insti
Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) https://clinicalinfo.hiv.gov/en/glossary/non-nucleoside-reverse-transcriptase-inhibitor-nnrti
Strategies to Prevent Weight Gain Among Adults https://pubmed.ncbi.nlm.nih.gov/23638485/
Tenofovir Alafenamide (TAF) Clinical Pharmacology https://pubmed.ncbi.nlm.nih.gov/35146360/
Associations Between Integrase Strand-Transfer Inhibitors and Cardiovascular Disease in People Living With HIV: A Multicentre Prospective Study From the RESPOND Cohort Consortium https://pubmed.ncbi.nlm.nih.gov/35688166/
Adipokines, Weight Gain and Metabolic and Inflammatory Markers After Antiretroviral Therapy Initiation: AIDS Clinical Trials Group (ACTG) A5260s https://pubmed.ncbi.nlm.nih.gov/34117756/
Is Tenofovir Disoproxil Fumarate Associated With Weight Loss? https://pubmed.ncbi.nlm.nih.gov/34848586/
Switching From Boosted PIs to Dolutegravir Decreases Soluble CD14 and Adiponectin in High Cardiovascular Risk People Living With HIV https://pubmed.ncbi.nlm.nih.gov/34120186/
Adiponectin: A Fat Cell Hormone That Promotes Insulin Sensitivity https://www.medscape.org/viewarticle/438373
Glucagon-like Peptide-1 Analogues: An Overview https://pubmed.ncbi.nlm.nih.gov/23869296/
Dolutegravir Plus Two Different Prodrugs of Tenofovir to Treat HIV https://pubmed.ncbi.nlm.nih.gov/31339677/
Weight and Metabolic Changes After Switching From Tenofovir Alafenamide (TAF)/Emtricitabine (FTC)+Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)/FTC+DTG and TDF/FTC/Efavirenz (EFV) to TDF/Lamivudine (3TC)/DTG https://pubmed.ncbi.nlm.nih.gov/36519389/
The ADVANCE Study: A Groundbreaking Trial to Evaluate a Candidate Universal Antiretroviral Regimen https://pubmed.ncbi.nlm.nih.gov/28538284/